spesolimab
DrugSolution
NCT Number: NCT03648541
To evaluate the long-term safety of BI 655130 (SPESOLIMAB) in patients with moderate to severely active ulcerative colitis, who have completed treatment in previous trials
To evaluate the long-term efficacy of BI 655130 (SPESOLIMAB) in patients with moderate to severely active ulcerative colitis, who have completed treatment in previous trials
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 2
Ordensklinikum Linz GmbH - Barmherzige Schwestern, Linz, Austria
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Solution
Time frame: From first maintenance treatment until last maintenance treatment, plus residual effect period (REP) of 112 days, up to 1550 days.
Exposure adjusted rate of participants reporting a treatment emergent adverse event (TEAE).
The exposure adjusted incidence rate (per 100 subject years) of a selected treatment emergent adverse event is defined as the number of subjects experiencing the adverse event per treatment group during time at risk divided by the total time of subjects at risk in that treatment group to contribute the event to the analysis multiplied by 100 (per 100 subject years).
Only participants receiving maintenance treatment were analysed for this endpoint.
Time frame: Up to 336 weeks
Proportion of patients with clinical remission at Week 336 of maintenance treatment. Clinical remission was defined as rectal bleeding score (RBS) = 0, modified endoscopic subscore [mESS] ≤1, stool frequency score (SFS) = 0 or 1 and drop ≥1 from baseline, and modified mayo clinical score ((MCS) ≤2).
Boehringer Ingelheim
Industry
An Open Label, Long Term Safety Trial of BI 655130 (SPESOLIMAB) Treatment in Patients With Moderate to Severely Active Ulcerative Colitis Who Have Completed Previous BI 655130 Trials
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04630028
Colitis, Colitis, Ulcerative
Wilmington, Delaware, United States
View Trial DetailsNCT04779307
Colitis, Colitis, Ulcerative
Phoenix, Arizona, United States
View Trial DetailsNCT04647578
Colitis, Colitis, Ulcerative
Lille, France
View Trial DetailsNCT06049017
Colitis, Colitis, Ulcerative
Anaheim, California, United States
View Trial Details